Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Shota Omori

Citation

Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265

Authors

S. Omori1, H. Kenmotsu1, A. Notsu2, K. Mori2, T. Tsushima3, Y. Satake4, Y. Miki5, M. Abe6, M. Ogiku7, T. Nakamura8, M. Takagi9, H. Ochiai10, H. Yasui3, T. Takahashi1

Author affiliations

  • 1 Division Of Thoracic Oncology, Shizuoka Cancer Center, 411-8777 - Nagaizumi-cho Sunto-gun/JP
  • 2 Clinical Trial Coordination Office, Shizuoka Cancer Center, 411-8777 - Nagaizumi-cho Sunto-gun/JP
  • 3 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Nagaizumi-cho Sunto-gun/JP
  • 4 Department Of Respitratory Medicine, Shizuoka City Shizuoka Hospital, 420-8630 - Shizuoka/JP
  • 5 Department Of Respiratory Medicine, Seirei Hamamatsu General Hospital, 430-8558 - Hamamatsu/JP
  • 6 Division Of Gynecology, Shizuoka Cancer Center, 411-8777 - Nagaizumi-cho Sunto-gun/JP
  • 7 Gastroenterological Surgery, Hamamatsu Medical Center, 432-8580 - Hamamatsu/JP
  • 8 Surgery, Fujieda Municipal General Hospital, 426-8677 - Fujieda/JP
  • 9 Department Of Gastroenterological Surgery, Shizuoka General Hospital, 420-8527 - Shizuoka/JP
  • 10 Department Of Gastroenterological Surgery, Iwata City Hospital, 438−8550 - Iwata/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1189

Background

Venous thromboembolism (VTE) is frequently observed in patients with solid tumor. Previous report suggested that the prevalence of VTE varied among different ethnic groups. The objectives of this prospective observational study are to estimate the prevalence of VTE in Japanese patients with advanced solid tumor based on intensive screening, using CT scans, lower-extremity ultrasonography, and D-dimer testing.

Methods

Eight-hundred sixty Japanese patients were enrolled into this study. Adult (age ≥20 years) patients with metastatic or locally advanced solid tumor without anticoagulant therapy, who are planning to receive chemotherapy during 4 weeks, PS 0-2 were eligible in this study. Evaluations of VTE were performed at enrollment, 12 and 24 weeks. Primary endpoint was the prevalence of VTE for 24 weeks, and secondary endpoints included the incidence of VTE (at enrollment, 12 weeks, 24 weeks), VTE for 24 weeks by primary cancer site, symptomatic VTE for 24 weeks, pulmonary thromboembolism (PE), treatment of VTE.

Results

The median age was 68 years (range 28-96 years), 34% female, 46/45/8% performance status 0/1/2. Primary cancer site included lung (71%), gastrointestinal (GI) (15%), hepatobiliary and pancreatic (HP) (5%), and gynecological (3%). The prevalence of VTE for 24 weeks was 22.6% (95%CI: 19.8-25.5%). The incidences of VTE were 11.3% (97/858) at enrollment, 16.8% (134/799) at 12 weeks, 14.1% (101/716) at 24 weeks. Among 761 patients without VTE at enrollment, 97 (12.7%) showed VTE after the start of chemotherapy. The prevalence of VTE for 24 weeks was 24.1% in patients with lung, 17.7% with GI, 25.6% with HP, and 32.1% in gynecological cancer. Symptomatic VTE for 24 weeks was observed in 4.0%, and PE was in 1.0%. Treatment of anticoagulant for VTE was started in 15.0% (129/858) after enrollment in this study.

Conclusions

This prospective observational study showed that prevalence of VTE was relatively high in Japanese patients with advanced solid tumor under intensive screening, compared with previous reports. Although most of patients with VTE were asymptomatic, prophylactic anticoagulant therapies may be considered in this study population.

Clinical trial identification

UMIN000015243.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.